These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Epstein JI; Feng Z; Trock BJ; Pierorazio PM Eur Urol; 2012 May; 61(5):1019-24. PubMed ID: 22336380 [TBL] [Abstract][Full Text] [Related]
63. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260 [TBL] [Abstract][Full Text] [Related]
64. Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer. Greenland NY; Zhang L; Cowan JE; Carroll PR; Stohr BA; Simko JP J Urol; 2019 Jul; 202(1):90-95. PubMed ID: 30810466 [TBL] [Abstract][Full Text] [Related]
65. Significance of Number and Localization of Positive Core Biopsies for the Identification of Prostate Cancer Eligible for Active Surveillance. Helpap B; Ringli D; Gevensleben H Anal Quant Cytopathol Histpathol; 2016 Feb; 38(1):9-16. PubMed ID: 27363061 [TBL] [Abstract][Full Text] [Related]
66. [Concordance evaluation of gleason score between laparoscopic prostatectomy and needle biopsy specimens]. Cichocki M; Konecki T; Jabłonowski Z Wiad Lek; 2018; 71(6):1193-1199. PubMed ID: 30267499 [TBL] [Abstract][Full Text] [Related]
67. Correlation of Gleason scores between needle-core biopsy and radical prostatectomy specimens in patients with prostate cancer. Hsieh TF; Chang CH; Chen WC; Chou CL; Chen CC; Wu HC J Chin Med Assoc; 2005 Apr; 68(4):167-71. PubMed ID: 15850066 [TBL] [Abstract][Full Text] [Related]
69. Random forest-based modelling to detect biomarkers for prostate cancer progression. Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781 [TBL] [Abstract][Full Text] [Related]
70. Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression. Warrick JI; Humphrey PA Am J Surg Pathol; 2013 Nov; 37(11):1709-14. PubMed ID: 23797726 [TBL] [Abstract][Full Text] [Related]
71. Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue. Medlow PW; Steele CJ; McCavigan AM; Reardon W; Brown CM; Lambe SM; Ishiy FAA; Walker SM; Logan GE; Raji OY; Berge V; Katz B; Kay EW; Sheehan K; Watson RW; Harkin DP; Kennedy RD; Knight LA BMC Med Genomics; 2018 Dec; 11(1):125. PubMed ID: 30591067 [TBL] [Abstract][Full Text] [Related]
72. Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome. Cattrini C; Rubagotti A; Nuzzo PV; Zinoli L; Salvi S; Boccardo S; Perachino M; Cerbone L; Vallome G; Latocca MM; Zanardi E; Boccardo F Clin Genitourin Cancer; 2018 Dec; 16(6):e1257-e1265. PubMed ID: 30170989 [TBL] [Abstract][Full Text] [Related]
73. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? Makarov DV; Sanderson H; Partin AW; Epstein JI J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053 [TBL] [Abstract][Full Text] [Related]
74. Twelve Core Template Prostate Biopsy is an Unreliable Tool to Select Patients Eligible for Focal Therapy. Fumadó L; Cecchini L; Juanpere N; Ubré A; Lorente JA; Alcaraz A Urol Int; 2015; 95(2):197-202. PubMed ID: 25896142 [TBL] [Abstract][Full Text] [Related]
75. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer. Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899 [TBL] [Abstract][Full Text] [Related]
76. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675 [TBL] [Abstract][Full Text] [Related]
77. Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome. Bismar TA; Alshalalfa M; Petersen LF; Teng LH; Gerke T; Bakkar A; Al-Mami A; Liu S; Dolph M; Mucci LA; Alhajj R BJU Int; 2014 Feb; 113(2):309-19. PubMed ID: 24006850 [TBL] [Abstract][Full Text] [Related]
78. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort. Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006 [TBL] [Abstract][Full Text] [Related]
79. Initial diagnosis of insignificant cancer, high-grade prostatic intraepithelial neoplasia, atypical small acinar proliferation, and negative have the same rate of upgrade to a Gleason score of 7 or higher on repeat prostate biopsy. Prathibha S; Goyal KG; Zynger DL Hum Pathol; 2018 Sep; 79():116-121. PubMed ID: 29803813 [TBL] [Abstract][Full Text] [Related]